Please login to the form below

Not currently logged in
Email:
Password:

Lilly/Boehringer diabetes deal

Eli Lilly and Boehringer Ingelheim have announced a deal to develop and market several diabetes products including oral agents and basal insulins

Eli Lilly and Boehringer Ingelheim have announced a deal to jointly develop and market several diabetes products including oral agents and basal insulins.

The companies say the alliance will see the sharing of scientific expertise and business capabilities, with ongoing development costs for agreed compounds shared equally between the two companies.

Lilly already has a broad portfolio in diabetes, with products including Byetta (exenatide), whereas Boehringer are looking to expand into a new therapeutic area with cases of diabetes continuing to expand globally.

The compounds to be developed are all either in mid-stage or late-stage development, and include Boehringer's linagliptin and BI10773, both of which are oral diabetes agents. LY2605541 and LY2963016, two basal insulin analogues owned by Lilly, will also be developed by both companies.

The agreement will see Lilly make a one-off initial payment to Boehringer of €300m, with Boehringer eligible to receive up to €625m in milestone payments during the development and marketing of Boehringer's drugs.

Lilly will in turn be eligible to receive up to $650m from Boehringer following success-based regulatory milestones related to its two basal insulins.

Lilly could also receive up to $525m for milestone payments concerning an anti-TGF-beta monoclonal antibody should Boehringer choose to opt-in to the product's development process.

Dr John C Lechleiter, chairman and CEO, Lilly, commented on the agreement: "For Lilly, this alliance expands our range of offerings for people with diabetes, strengthens our diabetes care capabilities and offers the prospect of near-term revenue opportunities as we address the upcoming loss of patent exclusivity for several of our products."

11th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics